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Abstract
Background: Robotic stereotactic ablative radiotherapy (SABR) is currently under investigation as a noninvasive
treatment option for patients with renal cell carcinoma (RCC). For radiation therapy of RCC, tumor motion and the
need for high ablative doses while preserving the remaining renal parenchyma is a challenge. We aimed to analyze
the safety and efficacy of robotic radiosurgery in RCC in a specific difficult subgroup of patients with impaired renal
function.
Methods: We retrospectively identified all patients with RCC, treated with robotic SABR and motion compensation
in our institution between 2012 and 2017. Either single fraction SABR of 24 or 25 Gy or 3 fractions of 12 Gy
prescribed to the 70% isodose line was applied. Local control, overall survival, radiation side effects were evaluated
together with renal function and tumor motion.
Results: We analyzed data of 13 lesions treated in 10 patients with clear cell RCC and a mean age of 70.5 ± 13.6
years (range: 48–87). Prior to SABR, 8 patients underwent previous complete and/or partial nephrectomy, 7 patients
presented with chronic kidney disease ≥ stage 3. The median of minimum, mean and maximum planning target
volume doses were 23.2, 29.5 and 35.0 Gy for single fraction and 24.4, 42.5 and 51.4 Gy for the three fractions
regime. Persistent local control by robotic SABR was achieved in 9 out of 10 patients (92.3% of all lesions) within a
median follow-up period of 27 month (range: 15–54). One patient underwent nephrectomy due to progressive
disease and sufficient renal function of the contralateral kidney. Renal function remained stable with a mean
estimated glomerular filtration rate (eGFR) of 51.3 ± 19.7 ml/min at baseline and 51.6 ± 25.8 ml/min at follow-up. The
largest respiratory-induced tumor motion was seen in superior-inferior direction, compensated by the CyberKnife
with mean targeting errors of maximal 2.2 mm.
Conclusions: Robotic SABR is technically feasible for the treatment of RCC in preexisting kidney disease with good
local tumor control at about 2 years follow-up. Robotic SABR with motion tracking offers a valid treatment option
for patients, who are at increased risk for progression to end-stage renal disease due to partial nephrectomy or
ablative techniques.
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Background
Renal cell carcinoma (RCC) is the most common form
of kidney cancer and its incidence has risen in recent
years [1]. Due to increased incidental detection rates of
kidney tumors, more RCC are still confined to the kid-
ney at the time of diagnosis. The standard treatment for
Stage I RCC is a partial renal resection. Radical nephrec-
tomy is only performed for centrally located tumors or
when partial resection is not feasible. Patients with bilat-
eral tumors, contralateral recurrent tumor after unilat-
eral nephrectomy, metastases from RCC in the
contralateral kidney or preexisting chronic kidney dis-
ease are special candidates for partial nephrectomy. In
these patients preserving renal parenchyma is essential
to avoid chronic kidney disease.
As a possible therapeutic approach robotic stereotactic
ablative radiotherapy (SABR) is currently under investi-
gation as a non-invasive treatment option for patients
with RCC. Renal cell carcinoma is frequently reported as
a radio-resistant tumor. However, pathologic complete
responses have been described after ablative radiother-
apy previously [2]. Tumor motion and the need for high
ablative radiation doses while preserving the remaining
renal parenchyma, poses a major challenge. Robotic ra-
diosurgery allows continuous tumor tracking under free
breathing and therefore minimal gross tumor volume
(GTV) to planning target volume (PTV) margins are
needed. Robotic SABR for moving tumors is already
established as a standard treatment option for patients
with early stage non-small cell lung cancer [3, 4].
Although current data seem to demonstrate that SABR
provides good tumor control while preserving the renal
function [5, 6], most studies are limited to patients with
normal renal function. In this study, we analyzed the
safety and efficacy of image-guided CyberKnife (Accuray
Inc., Sunnivale, USA) radiosurgery in RCC in a specific
subgroup of patients with preexisting impaired renal
function. Feasibility and technical aspects of robotic
SABR will be provided as well.
Methods
Study design
Retrospective analysis of patient data was approved by
the Ethics Committee Campus Charité Mitte (EA1/233/
18). We identified all histology proven RCC patients,
who were treated with robotic SABR in our center be-
tween June 2012 and April 2017. We collected data on
patient characteristics regarding disease stage, preexist-
ing kidney disease, estimated glomerular filtration rate
(eGFR), clinical outcome, complications, local tumor
control and overall survival. Dose-volume parameters
were analyzed including prescription dose, fractionation,
treatment dose (Dmin, Dmean, Dmax,), GTV, PTV, new
conformity index (nCI), PTV coverage, tumor motion
and tracking accuracy.
Robotic SABR planning and delivery
The patients were referred to CyberKnife irradiation
from the nephrology department, all at increased risk for
progression to end-stage renal disease caused by further
invasive treatment. The decision to perform a robotic
SABR was recommended by a multidisciplinary urology
board review for patients who are at increased risk for
progression to end-stage renal disease due to partial
nephrectomy or other ablative techniques.
One gold fiducial marker (1.0 mm × 5.0 mm) was im-
planted within or close to each tumor using an 18-G
needle under computed tomography (CT)-guidance in
local anesthesia. A tissue sample was taken in the same
procedure if there was no prior pathology report avail-
able. High-resolution native thin-slice (1.0 mm) planning
CT was performed within a median of 8 days (range: 1–
21) after fiducial insertion to allow for fiducial settle-
ment [7]. For accurate tumor delineation, magnetic res-
onance images (MRI) were co-registered with the
planning CT and contouring was performed on all axial
slices. The GTV was defined as the tumor volume based
on CT and MR images. The clinical target volume
(CTV) was equivalent to the GTV. The PTV was ob-
tained by adding in median a 3 mm (range: 0–5 mm) iso-
tropic margin to the GTV. Depending on tumor size or
organs at risk (OAR) two different dose concepts were
used, either single fraction SABR of 24 or 25 Gy, or 36
Gy in 3 fractions (12 Gy/fraction) prescribed each to the
70% isodose covering the PTV. Treatment planning and
dose calculations were obtained by MultiPlan 4.6
(Accuray Inc., Sunnyvale, USA) using the Ray-tracing
algorithm.
The linear-quadratic model, assuming an a/ß ratio of
2.6–6.9 Gy for RCC [8], was used to calculate the bio-
logically equivalent dose (BED) and the equivalent dose
in 2 Gy fractions (EQD2). The calculated BED6.9 and
EQD26.9 encompassing the PTV for single fraction were
107.5 Gy and 83.3 Gy, and 98.6 Gy and 76.4 Gy for the 3-
fraction treatment.
Dose constraints for OAR for single fraction treat-
ments were as follows: < 5 cm3 of small bowel loops
could receive up to 10.0 Gy with a maximum point dose
of 19.0 Gy; for the extratumoral kidney parenchyma <
200 cm3 could receive up to 8.0 Gy. The normal tissue
constraints for three fractions were: < 5 cm3 could re-
ceive up to 16.0 Gy with a maximum point dose of 27.0
Gy for small bowel, and less than 33% of the remaining
kidney parenchyma could receive a total of 15.0 Gy. The
dose constraints for spinal cord, liver, stomach and large
intestine were set according to published standard limits
[9]. The nCI [(V70% ∙ VPTV)/V70%PTV
2], which describes
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the conformity between the prescription isodose and the
volume and shape of the PTV, was also used for treat-
ment plan evaluation.
Technical aspects
The CyberKnife System installed in July 2011 in Berlin
combines two systems, a lightweight linear accelerator
mounted on a robotic arm with 6-MV photon energy
and an image guidance system consisting of two orthog-
onally positioned x-ray cameras. For patient positioning,
an automatic tracking algorithm compares live x-rays
with digital reconstructed images from planning CT. For
respiratory motion compensation, the CyberKnife Syn-
chrony® Respiratory Motion Tracking System (MTS) was
used. Thereby, the external motion of LED markers lo-
cated on the chest of the patient was correlated with the
internal tumor motion represented by the fiducial pos-
ition and determined by the x-ray images. The individu-
ally measured correlation model is continuously updated
and synchronizes the radiation beam in real time such
that the beam always remains aligned with the target.
An accuracy of less than 1.0 mm is technically achieved
and allows clinicians to reduce safety margins signifi-
cantly, while eliminating the need for gating or breath-
hold techniques. During treatment, the motion patterns
for each patient were recorded in logfiles.
Follow-up and statistics
Clinical and radiological follow-up with CT or MRI was
frequently performed after robotic SABR and the latest
available follow-up was used in this analysis. For local
control the MRI scans were evaluated by the senior
physician in charge to verify treatment response. Tumor
response was analyzed using response evaluation criteria
in solid tumors (RECIST version 1.1). The treatment re-
sponse of each RCC was categorized using OsiriX MD
10.0 (Pixmeo SARL, Bernex, Switzerland) to compare
baseline MRI and planning CT with the latest available
follow up images in 1) complete remission (CR): no
measurable lesion; 2) partial remission (PR) defined as a
volume reduction ≥ 30%; 3) stable disease (SD); 4) pro-
gressive disease (PD) defined as a ≥ 20% increase in vol-
ume or ≥ 5mm increase in size. Local control (LC) was
calculated from the end of SABR until last available
follow-up or PD.
Overall survival (OS) was calculated from the end of
SABR until last follow-up or death. LC and OS were es-
timated using Kaplan-Meier curves. Common Termin-
ology Criteria for Adverse Event V4.03 (CTCAE) for
acute and late radiosurgery related side effects were re-
corded separately. Renal function at baseline and latest
available follow up was calculated according to the
chronic kidney disease epidemiology collaboration
(CKD-EPI) formula at baseline and last available follow
up.
Due to respiratory induced kidney motion, the motion
patterns and total targeting errors between the predicted
and the actual position of the tumor were evaluated.
Overall, the motion pattern and targeting accuracy of 19
out of 21 treatment sessions could be extracted. Motion
pattern evaluation and statistical analysis were done with
MATLAB 9.3 (The MathWorks, Inc., Natick, USA).
Results
Patient characteristics
Data of 13 lesions treated in 10 patients histologically
confirmed as clear cell RCC grade 1 or 2 were collected.
The mean age of patients who underwent robotic SABR
was 70.5 ± 13.6 years (range: 48–87). The female/male
ratio was 1:1. All patients treated with robotic SABR had
an ECOG performance status 1 or 2 and suffered from
chronic kidney disease (CKD). The median and mean
time interval between the first histological diagnosis of
RCC and SABR was 7.5 and 8.4 ± 6.0 years, respectively,
with a large range of 2 months to 19.7 years. Tumor
characteristics are summarized in Table 1. Seven pa-
tients had T1a (≤ 40mm) and 3 patients had larger tu-
mors (T3a). In 3 patients it remained unclear whether
the treated tumor was a metachronous RCC or a metas-
tasis from a previously occurred contralateral RCC. The
subsites of the 13 lesions were the upper, mid or lower
pole in 53.8%, close to the renal pelvis or extending to
the perinephric tissue in 15.4% each and infiltrating the
renal vein or close to the hilum in 7.7% each.
Prior to SABR, 8 out of 10 patients underwent surgery
or radiofrequency ablation (RFA) for their renal tumors,
6 of them had procedures done on both sides. Nephrec-
tomy was carried out in 5 patients, partial ipsilateral re-
section in 4 patients and contralateral resection in 3
patients. Previous RFA of the SABR treated kidney was
performed in 2 patients. Von Hippel-Lindau disease was
diagnosed in 2 patients. One patient had a RCC in his
kidney transplant. Three patients had a diabetes mellitus
type 2. CKD stage 2, 3 and 4 with an eGFR level below
90, 60, 45 ml/min was diagnosed in 3, 6 and one patient,
respectively (see Table 1 for preexisting kidney disease).
Treatment and Dosimetric analysis
The tumors had a median diameter of 28.8mm (range: 9–
70). Two patients had tumors larger than 40mm with
RCC extension into the renal vein or perinephric tissue.
The median GTV volume was 13.3 cm3 (range: 1.3–
108.4), the resulting median PTV was 22.1 cm3 (range:
3.8–190.3). Five patients received single fraction SABR of
24 or 25 Gy, 4 patients received 3 fractions of 12Gy every
other day and one patient with three lesions received both
regiments. The patient’s median of minimum, mean and
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maximum PTV dose was 23.2, 29.5 and 35.0 Gy for single
fraction and 24.4, 42.5 and 51.4 Gy for the three fractions
regimen, respectively. Dose-volume parameters and fur-
ther treatment characteristics including nCI and percent-
age of the PTV coverage are summarized in Table 2.
Each robotic SABR treatment was done as an out-
patient procedure with delivery times between 46 min
and 86 min per session. For single session treatments,
the mean total treatment time was 62 ± 15 min, fraction-
ated treatments took in total 184 ± 33min (61 ± 11min
per fraction). All patients completed their treatment.
Tumor response
Local control (CR, PR and SD) by robotic SABR therapy
was achieved in 9 out of 10 patients and 92.3% of all le-
sions within the median follow-up period of 27month
(range: 15–54). A representative example of the tumor
response and treatment plan is shown in Fig. 1. Whereas
SD was observed in 38.5% of the treated lesions, PR was
observed in 30.8% and CR in 23.1% (Table 2). However,
there was no difference in SD or PR between the one frac-
tion or three fractions regiment. The only local treatment
failure occurred in one lesion (7.7%) 5month after SABR.
Four patients with metastases to other organs at time
of radiosurgery or during follow-up had additional adju-
vant systemic treatment. Out of 10 patients 8 were alive
at the last available follow-up. Two patients with pro-
gressive metastatic disease died 15 and 16months after
SABR. Kaplan-Meier Curves for local control and overall
survival are shown in Fig. 2.
Renal function and toxicity
Typical normal tissue dose constraints were within the
range mentioned. Over a median follow-up period of 22
Table 1 Tumor characteristics and preexisting kidney disease in patients with renal cell carcinoma
Case Size (mm) Primary tumor Tumor location Baseline CKD stage First line treatment /
Preexisting kidney disease
#1 32 cT1a/DD metastasis close to renal pelvis 3b Nephrectomy, RFA and embolisation ipsilateral





3b Nephrectomy, partial resection ipsilateral / short term dialysis, DM type 2
#4 26 cT1a upper pole 2 RPGN, kidney transplant
#5 70 cT3a infiltrating renal vein 2 Partial resection contralateral
#6 36 cT1a mid pole 4 Nephrectomy
#7 36 cT1a lower pole 3a partial resection contralateral, multiple RFA ipsilateral / VHL
#8 39 cT1a close to renal pelvis 3a partial resection ipsi- and contralateral / VHL




cT3a/DD metastasis lower pole
extends to perinephric tissue
close to hilum
3b Nephrectomy, partial resection ipsilateral
RFA Radiofrequency ablation, CKD chronic kidney disease, DM diabetes mellitus, RPGN rapidly progressive glomerulonephritis, VHL von Hippel-Lindau disease
Table 2 Dose-volume and follow-up parameters for robotic stereotactic ablative body radiotherapy
Case GTV (cm3) PTV (cm3) Margin (mm) Dose (Gy) PTV coverage (%) nCI Follow-up (month) Local control
#1 8.2 17.9 4 1 × 24 97.8 1.07 54 SD















#4 14.3 24.6 3 1 × 25 99.9 1.06 33 SD
#5 108.4 190.3 5 3 × 12 92.0 1.23 25 SD
#6 13.2 22.7 3 1 × 25 99.5 1.13 15 SD
#7 9.2 17.4 3 3 × 12 98.3 1.14 32 SD
#8 45.5 88.4 5 3 × 12 86.0 1.40 30 PD






















GTV Gross tumor volume, PTV planning target volume, nCI new conformity index, SD stable disease, PR partial remission, CR complete remission, PD
progressive disease
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month (range: 4–51) renal function remained stable with
a mean serum creatinine of 1.4 ± 0.5 mg/dl (eGFR 51.3 ±
19.7 ml/min) at baseline and 1.5 ± 0.8 mg/dl (eGFR
51.6 ± 25.8 ml/min) at follow-up (Fig. 3). One patient
underwent nephrectomy due to progressive disease after
SABR with three fractions of 12 Gy and sufficient renal
function of the contralateral kidney. One patient devel-
oped mild abdominal pain (grade 1) and another one
diarrhea and abdominal distension (grade 1). All symp-
toms occurred in the two patients with tumors larger
than 40mm. No patient developed CTCAE grade 2 or
higher toxicity or needed hemodialysis.
Tumor motion tracking
Each patient got one gold fiducial implanted per lesion.
Two patients had 2 and 3 gold fiducials for multiple le-
sions. There were no side effects with marker placement
in the kidney or difficulties with marker migration ob-
served. To position the patient as in planning CT, he
was first aligned using the bony spine structures. After-
wards the position of the fiducial was tracked. The ma-
jority of the lesions (92.3%) were treated using MTS for
motion compensation. The only robotic SABR done
without tumor motion tracking was performed in a kid-
ney transplant located in the left iliac fossa where no re-
spiratory motion was suspected. For all patients,
treatment was performed in “free-breathing”, the largest
respiratory-induced tumor motion was seen in superior-
inferior direction with magnitudes between 3.0 mm and
24.7 mm. The left/right and anterior/posterior displace-
ments of the tumor ranged from 0.7 to 10.6 mm, and 1.6
to 14.6 mm, respectively (Fig. 4). This motion was com-
pensated by the CyberKnife with mean targeting errors
over the complete treatment time of maximal 2.2 mm.
Discussion
In this retrospective study the efficacy of robotic SABR
was assessed retrospectively in 10 patients with RCC and
Fig. 1 A representative case of a renal cell carcinoma. a Demonstrates a representative image before radiotherapy and b the treatment plan with
exemplary planning computed tomography image in axial view with the treatment plan. Single fraction 25 Gy was prescribed to 70% isodose line
(in green) to treat planning target volume shown in red line. The yellow and white circle lines represent the remaining isodose lines until 20% in
blue. c shows an image 2 years after robotic stereotactic ablative radiotherapy
a b
Fig. 2 Kaplan-Meier curves. a Shows overall survival and b local control for renal cell carcinoma patients after robotic stereotactic ablative radiotherapy
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moderate to severe chronic kidney disease. Our study
demonstrates that this minimal invasive and highly so-
phisticated treatment method provides good response
rates and local control with negligible toxicity. SABR
with motion compensation is a nephron-sparing treat-
ment that perfectly adapts to patients with RCC and sig-
nificant preexisting chronic renal failure.
Our results concerning local tumor control in 92.3%
of all lesions and mild toxicity appear to be consistent
with those available in the literature. A previous system-
atic review of 126 patients described a weighted local
control rate of 94% and a grade 3 toxicity rate of 3.8%
[10]. Since that study, 3 single-institution, prospective
studies of 19 patients [11], 40 patients [2], and 33 pa-
tients [12] have reported similar findings, with local con-
trol rates ranging from 98 to 100% and grade > 3
toxicity rates from 0 to 15.8%. Recently, 9 centers across
Germany, Australia, the United States, Canada, and
Japan formed an International Radiosurgery Oncology
Consortium for Kidney and reported data of 223 patients
[6]. The rates of LC, cancer-specific survival, and
progression-free survival at 2 and 4 years were 97.8, 95.7,
77.4% and 97.8, 91.9, 65.4%, respectively. Multi-fraction
SABR was associated with poorer progression-free sur-
vival and worse cancer-specific survival. Grade 1 and 2
toxicities were reported for 35.6% of patients whereas
grade 3 and 4 toxicities were recorded in only 1.3% [6].
In patients with bilateral tumors or contralateral
tumor recurrences after unilateral nephrectomy or par-
tial resection treatment is especially challenging. The re-
section of the remaining kidney consecutively leads to
the progression of chronic kidney disease including the
need for hemodialysis treatment. In such cases, minim-
ally invasive ablative techniques such as cryosurgery, ra-
diofrequency ablation and SABR are possible alternatives
to nephrectomy. A 2016 systematic review and meta-
analysis reporting on survival across management strat-
egies demonstrated a 95 to 100% cancer specific survival
after nephrectomy and thermal ablation with a median
follow-up period of 22 to 120 months. Whereas, for tu-
mors more than 40mm (T1b) survival rates decrease to
around 90% and for tumors more than 70 mm (T2) be-
tween 82.5 and 86.7% [13]. A mostly retrospective data
analysis by Kunkle and Uzzo [14] showed local tumor
progression rates of 12.9% after RFA and 5.2% after renal
cryoablation. In our series, tumor progression was
Fig. 3 Kidney function at baseline and follow-up. Estimated glomerular filtration rates (eGFR) before stereotactic ablative radiotherapy (pre SABR)
and latest available follow-up (post SABR)
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recorded in 7.7% of all lesions, accordingly in one out of
10 patients (10%). In this case the tumor size was above
the median, located close to renal pelvis and the PTV
coverage was less than 90%.
Notably, renal function remained stable following
treatment in all patients despite the high doses of radi-
ation delivered to the kidney. This result raises two con-
siderations. Firstly, preservation of renal function was
assumed to be due to compensatory mechanisms of the
contralateral kidney and the spared ipsilateral kidney
volume described as renal functional reserve [15]. These
results also suggest that it might be possible to rely on a
compensatory capacity of the ipsilateral kidney in pa-
tients who already had contralateral nephrectomy and
that, whenever oncologically suitable, a selective ap-
proach aimed to avoid post-treatment severe chronic
kidney disease should be pursued. A second point con-
cerns the radiation tolerance of the peritumoral kidney
and the reliability of tumor tracking in robotic SABR.
Cassady [16] proposed a threshold dose of 15 Gy for
renal injury based on data of bilateral whole kidney ir-
radiation in 3 fractions. Nevertheless, ours and other
previous studies demonstrate a good tolerance to higher
doses and stable kidney function. The prescribed dose
(1 × 24–25 Gy or 3 × 12 Gy prescribed to the 70% iso-
dose) was relatively high in order to overcome the radio-
resistance of RCC. The fraction number and prescribed
dose of the two large studies from Staehler et al. [2] and
Sun et al. [17] were similar to our dose concepts. Over-
all, they treated 80 patients with either 25 Gy in one
fraction or 38 Gy in 3 fractions prescribed to the 70 or
80% isodose line. Both studies reported only grade 1 side
effects with > 90% local control in a relatively short
follow-up.
Svedman et al. [18] evaluated kidney injury following 3
fractions SABR in 7 patients with primary or metastatic
renal disease with only one functioning kidney. In 5 pa-
tients, kidney function remained unaffected after SABR,
with a kidney volume of 37.3% receiving 15 Gy (V15),
whereas 2 patients exhibited modest changes in renal
function without the requirement for medical interven-
tion or hemodialysis. In SABR patients, a V15 limited to
less than one third of the normal single remaining kid-
ney could be an appropriate dose-volume constraint in
patients with preexisting kidney disease. We therefore
considered this dose constraint in our series for the
three-fraction regiment.
Furthermore, the high doses used and the treatment
result in terms of remission, local control and sparing of
renal function, demonstrate that the robotic SABR is
highly reliable in terms of targeting precision and dose
delivery. According to our data, the median targeting ac-
curacy was within 2.2 mm. This provided us an import-
ant information regarding the margins to be used. In
Fig. 4 A diagram of motion amplitudes. Maximal motion amplitudes of all treatment sessions in inferior/superior (Inf/Sup), left/right (Lft/Rgt) and
anterior/posterior (Ant/Pos) direction in mm
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fact, we believe that, unlike margins of up to 10mm, as
used in other studies, a moderate expansion of the
tumor (i.e. 3.0 mm) is sufficient for the CyberKnife
MTS. Since only one marker was implanted, rotations
could neither be directly detected nor corrected. How-
ever, geometric calculations have shown that a 3.0 mm
margin appears to be sufficient also if small rotations
(< 5 °) occur.
Limitations
This study has several limitations. This is a retrospective
series with a limited number of cases collected and a
relatively short follow-up for renal function. Neverthe-
less, it should be considered as a proof-of-concept study
for SABR on patients with impaired renal function gain-
ing satisfactory results and providing a low risk for
treatment-related side effects.
Conclusion
Robotic SABR is technically feasible for the treatment of
early stage RCC in patients with preexisting kidney dis-
ease with good local control at short term follow-up. As
an outpatient procedure, it may prevent (treatment re-
lated) loss of renal function with only mild side effects.
Therefore robotic SABR with motion tracking represents
a valid treatment option for these patients, who are at
increased risk for progression to end-stage renal disease
due to partial nephrectomy or other ablative techniques.
Further studies are needed but warranted to determine
long-term results of this treatment.
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